Press Releases

 
Press Releases
  Date Title View
Jan 12, 2018
BERKELEY, Calif., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on January 10, 2018 the Compensation Committee of Dynavax's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 57,000 shares of common stock to six new employees. These awards were gran...
Jan 8, 2018
BERKELEY, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] is now available in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV...
Jan 4, 2018
BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 11, 2018 ...
Dec 5, 2017
BERKELEY, CA -- (Marketwired) -- 12/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved (i) the grant of inducement stock options to purchase an aggregate 73,800 shares of common stock and (ii) an inducement restricted stock unit award...
Nov 27, 2017
BERKELEY, CA -- (Marketwired) -- 11/27/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference this week in Boston, MA. The presentation will be webcast live and will occur on Thursday, November 30, 2017 at 2:2...
Nov 9, 2017
BERKELEY, CA -- (Marketwired) -- 11/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLIS...
Nov 3, 2017
BERKELEY, CA -- (Marketwired) -- 11/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2017. Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to ne...
Oct 19, 2017
BERKELEY, CA -- (Marketwired) -- 10/19/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC). This multi-center, open label trial is designed to e...
Sep 5, 2017
BERKELEY, CA -- (Marketwired) -- 09/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the company will present at two upcoming investor conferences in September. NewsMakers in the Biotech Industry Investor ConferenceFriday, September 8, 2017 in New York at 8:30 a.m. Eastern Time ...
Aug 15, 2017
BERKELEY, CA -- (Marketwired) -- 08/15/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares wer...
1
...
NextLast
= add release to Briefcase